Koldioxidneutral läkemedelsindustri : BECCS som en möjlighet för att uppnå nettonollutsläpp på en produktionssite

Industries have faced challenges trying to lower carbon emissions and reach climate goals solely with energy efficiency and renewable energy sources but there are still some emissions that will not be mitigated by this. The purpose of this work has been to evaluate bio-energy with carbon capture and storage with co-combustion in a current study as a way to breach the gap and achieve net zero emissions on AstraZenecas production site Snäckviken. A carbon audit based on GHG Protocol has been performed to evaluate the total emissions at the site. Energy calculations were performed based on the possibilities of co-combustion with waste solvent and biofuel to produce process steam. With the flue gas characteristics for the combustion, calculations for a post combustion carbon capture plant using MEA solvent was made. An economic evaluation has been performed based on a reference plant and carbon captured for the current study. The results showed that the carbon capture lowered the emissions for the production site from 1 020 tons CO2 per year to - 2 400 tons CO2 at a cost of 1 360 SEK/tons CO2. The CO2 avoidance cost was high compared to other studies due to lower capacity. However, great savings could be m ade from handling the waste solvent on site instead of paying for the destruction of the waste. Therefore, a carbon capture plant could still be feasible for the current study